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Abstract
Corticotropin-releasing factor (CRF, nomenclature as agreed by the NC-IUPHAR subcommittee on
Corticotropin-releasing Factor Receptors [30]) receptors are activated by the endogenous peptides
corticotrophin-releasing hormone, a 41 amino-acid peptide, urocortin 1, 40 amino-acids, urocortin 2, 38 amino-
acids and urocortin 3, 38 amino-acids. CRF1 and CRF2 receptors are activated non-selectively by CRH and
UCN. CRF2 receptors are selectively activated by UCN2 and UCN3. Binding to CRF receptors can be conducted
using radioligands [125I]Tyr0-CRF or [125I]Tyr0-sauvagine with Kd values of 0.1-0.4 nM. CRF1 and CRF2
receptors are non-selectively antagonized by α-helical CRF, D-Phe-CRF-(12-41) and astressin. CRF1 receptors
are selectively antagonized by small molecules NBI27914, R121919, antalarmin, CP 154,526, CP 376,395. CRF2
receptors are selectively antagonized by antisauvagine and astressin 2B.
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This is a citation summary for Corticotropin-releasing factor receptors in the Guide to Pharmacology database
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which are given here under database links.
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